Advanced Search
Protective Effect of Cyclovirobuxine D on Death of 6-Hydroxy-Dopamine-Induced PC12 Cells[J]. Journal of China Pharmaceutical University, 2004, (6): 81-83.
Citation: Protective Effect of Cyclovirobuxine D on Death of 6-Hydroxy-Dopamine-Induced PC12 Cells[J]. Journal of China Pharmaceutical University, 2004, (6): 81-83.
shu

Protective Effect of Cyclovirobuxine D on Death of 6-Hydroxy-Dopamine-Induced PC12 Cells

More Information
    Graphical Abstract
    • Abstract
  • AIM:To investigate the nerve protective effect and mechanism of cyclovirobuxine D (CVB-D) on 6-hydroxy-dopamine(6-OHDA)-induced death of PC12 cells.METHOD: The viability of PC12 cells was investigated by MTT. The uptake of glutamate into PC12 cells was me
    • FullText(HTML)
    • References (0)
    • Related Articles

  • Related Articles

    [1]YAO Lei, QU Linlin, FAN Daidi. Effects of rare ginsenoside on idiopathic pulmonary fibrosis[J]. Journal of China Pharmaceutical University, 2023, 54(5): 607-613. DOI: 10.11665/j.issn.1000-5048.2023042002
    [2]HUANG Zhicheng, YE Liu, DU Yu, GU Hongfeng, GAO Fanyun, ZHU Qihua, XU Yungen. Design, synthesis and biological evaluation of PARP-1/PI3K dual-target inhibitors[J]. Journal of China Pharmaceutical University, 2023, 54(4): 450-460. DOI: 10.11665/j.issn.1000-5048.2023050301
    [3]WANG Yanmei, YANG Lei, XIN Xiaofei, YIN Lifang. Combination therapy and drug delivery strategies for treatment of non-alcoholic fatty liver disease[J]. Journal of China Pharmaceutical University, 2022, 53(4): 423-432. DOI: 10.11665/j.issn.1000-5048.20220405
    [4]LI Xiaoshi, WU Xunxun, ZHENG Zuguo, YANG Hua, LI Ping. Advances of long noncoding RNAs in myocardial fibrosis[J]. Journal of China Pharmaceutical University, 2020, 51(6): 646-654. DOI: 10.11665/j.issn.1000-5048.20200602
    [5]KE Ke, JIANG Wenli, WANG Yu, ZHU Jingyu, JIN Jian. Study on the bioactivity against hematologic malignancies and theoretical binding mechanism of a novel PI3K inhibitor JN-65[J]. Journal of China Pharmaceutical University, 2019, 50(4): 410-416. DOI: 10.11665/j.issn.1000-5048.20190405
    [6]CAI Yanfei, WAN Aini, CHEN Yun, JIN Jian. Anti-liver fibrosis activities of the extracellular domain of transforming growth factor beta type II receptor fusion protein in vivo[J]. Journal of China Pharmaceutical University, 2019, 50(2): 246-252. DOI: 10.11665/j.issn.1000-5048.20190217
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]WAN Aini, XU Dongsheng, CAI Yanfei, CHEN Yun, JIN Jian, LI Huazhong. Anti-liver fibrosis activities of human insulin-like growth factor-1 in vitro[J]. Journal of China Pharmaceutical University, 2017, 48(4): 476-482. DOI: 10.11665/j.issn.1000-5048.20170413
    [9]DAI Li, ZHANG Lu, JI Hui, KONG Xiang-wen. Therapeutic effects of ZK14，a novel nitric oxide donating biphenyldicarboxylate derivative，on hepatic fibrosis in rats[J]. Journal of China Pharmaceutical University, 2009, 40(3): 254-257.
    [10]Danshen Inhibiting Isoproterenol Induced Cardiac Hypertrophy and Fibrosis in Mice and its Mechanisms[J]. Journal of China Pharmaceutical University, 2003, (6): 84-87.

Catalog

    Get Citation
    PDF
    XML
    Article views (983) PDF downloads (714) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：454423

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return